{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:20:56Z","timestamp":1787761256104,"version":"build-2784847793"},"reference-count":12,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,9,5]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Immune-mediated necrotising myopathy is a subtype of idiopathic inflammatory myopathy characterised by muscle fibre necrosis without significant inflammatory infiltrate. Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) myopathy is seen in 6%\u201310% of idiopathic inflammatory myopathy and is diagnosed in the context of elevated serum creatine kinase levels, proximal muscle weakness and anti-HMGCR autoantibodies. We recently encountered a 61-year-old man with anti-HMGCR myopathy with an atypical skin manifestation, partially responsive to triple therapy with steroids, intravenous immunoglobulin (IVIG) and rituximab. To our knowledge, there have been only four reported cases of skin rash associated with anti-HMGCR myopathy. Our case demonstrates the importance of recognising atypical manifestations of anti-HMGCR myopathy. Early addition of IVIG and rituximab is also critical in patients not responding to steroid monotherapy. Delay in achieving remission leads to prolonged steroid use, lower likelihood of beginning physical therapy and overall worse clinical outcomes.<\/jats:p>","DOI":"10.1136\/bcr-2021-243728","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T12:00:41Z","timestamp":1632139241000},"page":"e243728","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Atypical presentation of anti-HMGCR myopathy"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6775-0776","authenticated-orcid":false,"given":"Rahul","family":"Karna","sequence":"first","affiliation":[{"name":"Internal Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Singh","sequence":"additional","affiliation":[{"name":"Internal Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Marshall","sequence":"additional","affiliation":[{"name":"Pathology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Johnston","sequence":"additional","affiliation":[{"name":"Internal Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"key":"2025082722343253000_14.9.e243728.1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-Mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025082722343253000_14.9.e243728.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"2025082722343253000_14.9.e243728.3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-313166"},{"key":"2025082722343253000_14.9.e243728.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.30156"},{"key":"2025082722343253000_14.9.e243728.5","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1* 11: 01 in anti\u2013hydroxymethylglutaryl\u2010coenzyme a reductase\u2013associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2025082722343253000_14.9.e243728.6","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.88.16_supplement.P2.125","article-title":"Clinical dermatomyositis associated with Anti-HMG-CoA reductase antibody positive immune mediated necrotizing myopathy: a case report (P2. 125)","volume":"88","author":"Lavian","year":"2017","journal-title":"Neurology"},{"key":"2025082722343253000_14.9.e243728.7","doi-asserted-by":"crossref","DOI":"10.1177\/2050313X20984120","article-title":"Statin-associated anti-HMGCR immune-mediated necrotizing myopathy with dermatomyositis-like features: a case report","volume":"8","author":"Lim","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"2025082722343253000_14.9.e243728.8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.annder.2018.12.010","article-title":"[Dermatomyositis-like syndrome revealing statin-induced necrotizing autoimmune myopathy with anti-HMGCR antibodies]","volume":"146","author":"Merlant","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"2025082722343253000_14.9.e243728.9","doi-asserted-by":"crossref","first-page":"E135","DOI":"10.1002\/mus.26072","article-title":"Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibody-positive necrotizing autoimmune myopathy with dermatomyositis-like eruption","volume":"57","author":"Parikh","year":"2018","journal-title":"Muscle Nerve"},{"key":"2025082722343253000_14.9.e243728.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1506163"},{"key":"2025082722343253000_14.9.e243728.11","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"key":"2025082722343253000_14.9.e243728.12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:34:38Z","timestamp":1756359278000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":12,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,20]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bcr-2021-243728"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243728","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}